However, CTLA-4 inhibitors act predominantly by enhancing the binding affinity between CD28 on T cells and B7-1/B7-2 on antigen-presenting cells (APCs), indirectly augmenting T cell anti-tumor activity [19, 20]. The gene discussed is CD80; the disease is neoplasm.